Maternal near miss

From WikiMD's WELLNESSPEDIA

Maternal near miss (MNM) refers to a situation where a woman nearly dies but survives a complication that occurred during pregnancy, childbirth or within 42 days of termination of pregnancy. The World Health Organization (WHO) has defined MNM as “a woman who nearly died but survived a complication that occurred during pregnancy, childbirth or within 42 days of termination of pregnancy”.

Definition[edit]

The World Health Organization (WHO) defines a maternal near miss as a woman who nearly died but survived a complication that occurred during pregnancy, childbirth or within 42 days of termination of pregnancy. The concept of maternal near miss is based on the idea that women who survive life-threatening conditions have experienced a near-miss event.

Criteria[edit]

The WHO has established criteria for identifying maternal near misses. These include clinical criteria, such as the woman being admitted to the intensive care unit (ICU), and management-based criteria, such as the use of blood products.

Epidemiology[edit]

The incidence of maternal near misses varies widely around the world, with higher rates in low- and middle-income countries. The WHO estimates that for every woman who dies in childbirth, 20 or 30 experience complications that can be classified as a maternal near miss.

Significance[edit]

The study of maternal near misses can provide valuable information about the quality of obstetric care and help identify areas for improvement. It can also provide insights into the causes of maternal mortality and morbidity.

See also[edit]



References[edit]


External links[edit]

Further reading[edit]

  • Say L, Souza JP, Pattinson RC (April 2009). "Maternal near miss--towards a standard tool for monitoring quality of maternal health care". Best Practice & Research. Clinical Obstetrics & Gynaecology. 23 (3): 287–96. doi:10.1016/j.bpobgyn.2009.01.007. PMID 19303368.
  • Pattinson RC, Hall M (September 2003). "Near misses: a useful adjunct to maternal death enquiries". British Medical Bulletin. 67: 231–43. doi:10.1093/bmb/ldg007. PMID 14711764.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.